Page last updated: 2024-11-08

isovaleryl-coenzyme a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID165435
CHEBI ID15487
SCHEMBL ID850285
MeSH IDM0068192

Synonyms (31)

Synonym
beta-methylbutyryl-coenzyme a
beta-methylbutyryl-coa
3'-phosphoadenosine 5'-{3-[(3r)-3-hydroxy-2,2-dimethyl-4-{[3-({2-[(3-methylbutanoyl)sulfanyl]ethyl}amino)-3-oxopropyl]amino}-4-oxobutyl] dihydrogen diphosphate}
3-methylbutyryl-coenzyme a
3-methylbutanoyl-coenzyme a
beta-methylbutanoyl-coa
beta-methylbutanoyl-coenzyme a
CHEBI:15487
3-methylbutanoyl-coa
6244-91-3
isovaleryl-coenzyme a
3-methylbutyryl-coa
C02939
ISOVALERYL-COA ,
s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-methylbutanethioate
s-(3-methylbutanoate) coenzyme a
coenzyme a, isovaleryl-
SCHEMBL850285
IVC ,
isovaleryl coenzyme a
coenzyme a, s-(3-methylbutanoate)
UYVZIWWBJMYRCD-ZMHDXICWSA-N
isovaleryl coa
LMFA07050336
s-(3-methylbutanoic acid
s-isovalerate coenzyme a
s-isovalerate coa
s-(3-methylbutanoate
s-{(3s,5s,9r)-1-[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-3,5-dioxido-10,14-dioxo-2,4,6-trioxa-11,15-diaza-3lambda~5~,5lambda~5~-diphosphaheptadecan-17-yl} 3-methylbutanethioate
Q3066403
DTXSID50978008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
methylbutanoyl-CoAAny member of the class of butanoyl-CoAs having methylbutanoyl as the acyl substituent.
short-chain fatty acyl-CoAA fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any short-chain fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Valine,Leucine and Isoleucine degradation ( Valine,Leucine and Isoleucine degradation )2936
3-Methyl-butanoyl-CoA + Acceptor = 3-Methylbut-2-enoyl-CoA + Reduced acceptor ( Valine,Leucine and Isoleucine degradation )22
superpathway of sterol biosynthesis050
leucine degradation I020
Valine, leucine and isoleucine degradation034
Biochemical pathways: part I0466
Amino acid metabolism094

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (17.24)18.7374
1990's5 (17.24)18.2507
2000's8 (27.59)29.6817
2010's11 (37.93)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.26 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]